Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy
Waldenstrom macroglobulinemia (WM) has no cure, but therapies can improve survival.
The diagnosis and treatment of Waldenström macroglobulinemia (WM) are the subjects of this two-part review, which aims to provide current and thorough knowledge of these topics. The first portion of the study, previously published, investigated the epidemiology, etiology, clinicopathological aspects, differential diagnosis, prognostic factors, and impact on WM-specific groups. Specifically, this second section examines both the standard consolidated method and the new therapeutic strategy to handle the complex topic of the treatment of WM.
WM is a rare B‑cell malignancy for which no curative therapy exists; therefore, treatment strategies aim to prolong survival, alleviate symptoms and prevent organ damage. Knowledge of effective first‑line and salvage regimens, as well as the molecular drivers (e.g., MYD88 and CXCR4 mutation status) that guide the choice of Bruton tyrosine kinase (BTK) inhibitors, informs clinical decision‑making and the design of future trials.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Waldenström Macroglobulinemia Clinical Trials
- European Consortium for Waldenström's Macroglobulinemia
- The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia
- Waldenstrom's Macroglobulinemia Clinical Trials and Research | Dana‑Farber Cancer Institute